Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax

Affiliations

• ¹ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan. kizutsu@ncc.go.jp.
• ² Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan.
• ³ Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
• ⁴ Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan.
• ⁵ Department of Hematology, Tohoku University Hospital, Miyagi, Japan.
• ⁶ Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
• ⁷ Department of Hematology, Saitama Medical University Hospital, Saitama, Japan.
• ⁸ Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
• ⁹ AbbVie GK, Osaka, Japan.
• ¹⁰ AbbVie GK, Tokyo, Japan.
• ¹¹ AbbVie, Inc, North Chicago, IL, USA.
• ¹² Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.